Jason Mouabbi, MD

Jason Aboudi Mouabbi, MD, discussed the importance of using ctDNA testing to inform treatment decision-making across breast cancer populations.

Explore the evolving treatment landscape for early-stage triple-negative breast cancer, highlighting innovative therapies and clinical trial insights.

Explore the latest advancements in antibody-drug conjugates for treating triple-negative breast cancer, addressing critical challenges and innovations.

Jason A. Mouabbi, MD, discusses the role of FES-PET/CT imaging in the diagnosis of lobular breast cancer.

Dr Mouabbi highlights the ways that ctDNA has evolved from a research tool to a potential clinical decision-making aid in breast cancer.

Experts discuss the transformative impact of antibody-drug conjugates (ADCs) in cancer treatment, emphasizing their growing role and the need for oncologists to adapt.

Experts discuss the need for better biomarker testing in ADC trials to ensure more patients benefit from targeted therapies.

Experts discuss the potential of maintenance strategies for antibody-drug conjugates in breast cancer, aiming to enhance patient outcomes and manage toxicity.

Explore the innovative world of antibody-drug conjugates, revolutionizing cancer treatment with targeted therapies and reduced side effects.

Explore the evolving landscape of antibody-drug conjugates (ADCs) for breast cancer treatment and the strategic sequencing of therapies.

Explore the latest findings on Phase 3 trials for metastatic triple-negative breast cancer, highlighting treatment efficacy and toxicity profiles.

A new drug shows promise in treating triple-negative breast cancer, significantly improving survival rates and offering hope for better treatment options.

Discover how novel antibody-drug conjugates effectively target brain metastases, offering hope for reducing CNS recurrences in cancer patients.

Jason Aboudi Mouabbi, MD, discusses neoadjuvant multi-agent chemotherapy in HER2+ breast cancer.

Jason A. Mouabbi, MD, discusses unmet needs and areas requiring further investigation in HER2-positive advanced breast cancer.

Panelists note that detecting low-level circulating tumor DNA (ctDNA) despite normal imaging presents a clinical challenge, requiring personalized management that balances early intervention with patient-centered communication, as this molecular signal offers a valuable window to detect and treat microscopic disease before overt recurrence.

Panelists highlight that advances in circulating tumor DNA (ctDNA) testing now enable detection of cancer at ultralow levels far earlier than traditional methods, offering new opportunities for timely intervention while emphasizing that negative results, though increasingly reliable, still require cautious interpretation to guide personalized treatment decisions.

Panelists emphasize that as circulating tumor DNA (ctDNA) testing becomes more integrated into clinical practice, careful interpretation, tailored testing schedules, and ongoing provider education are key to its effective use in personalized breast cancer care.

Panelists discuss the real-world challenges of managing patients with positive circulating tumor DNA (ctDNA) but no radiographic evidence of disease, emphasizing treatment intensification, genomic profiling for resistance mutations, dynamic monitoring, and the integration of ctDNA with imaging and biopsy to guide personalized breast cancer care.

Panelists discuss ongoing studies exploring circulating tumor DNA (ctDNA) use in the adjuvant breast cancer setting to detect recurrence earlier and guide therapy, highlighting advances in assay sensitivity, the choice between tumor-informed and tumor-agnostic tests, and the challenge of turning ctDNA’s strong prognostic value into actionable, outcome-improving interventions.

Panelists discuss how circulating tumor DNA (ctDNA) serves as a highly predictive prognostic biomarker in breast cancer, guiding personalized treatment intensification and informing important patient decisions while enhancing risk stratification and motivating proactive care despite ongoing research into its impact on long-term outcomes.

Panelists discuss how circulating tumor DNA (ctDNA) is becoming a vital biomarker in breast cancer, with its dynamic changes guiding personalized treatment decisions, serving as a surrogate end point in trials, enabling earlier detection of progression, and offering a less-invasive monitoring tool that complements imaging—especially benefiting patients with hard-to-monitor disease or those who are frail.

A panelist discusses how clinicians should exhaust all endocrine therapies plus targeted therapies before moving to chemotherapy or antibody-drug conjugates, while noting that different oral SERDs have varying adverse effect profiles that patients should be counseled about.

A panelist discusses how the EMBER-3 study results cannot be directly compared to those from EMERALD because of different patient populations, with EMBER-3 having fewer heavily pretreated patients and different baseline characteristics.

Panelists discuss how emerging data from studies like E-BLIS and I-SPY 2 validate circulating tumor DNA (ctDNA) as a powerful prognostic tool in early breast cancer, showing it can detect recurrence months before imaging and potentially refine risk stratification beyond traditional markers, though its role in guiding treatment decisions remains under active investigation.

Panelists discuss how circulating tumor DNA (ctDNA) monitoring provides a valuable lead time for detecting recurrence in early-stage breast cancer—especially hormone receptor–positive cases—yet requires careful patient counseling and integration with traditional prognostic tools, as its use for guiding treatment decisions remains nuanced and dependent on evolving clinical evidence.

Jason A. Mouabbi, MD, discusses the importance of achieving consensus for integrating CompassHER2-pCR data into early-stage HER2+ breast cancer management.

A panelist discusses how combination studies like ELEVATE are exploring elacestrant with other targeted therapies, showing promising results with ribociclib and everolimus combinations that are well-tolerated and efficacious.

A panelist discusses how real-world studies of elacestrant showed even better outcomes than clinical trials, with progression-free survival approaching 9 months, demonstrating the drug’s effectiveness in broader patient populations.

Panelists discuss how circulating tumor DNA (ctDNA) testing for molecular residual disease (MRD) offers a sensitive tool for detecting early breast cancer recurrence before clinical symptoms appear while emphasizing the importance of shared decision-making, patient education, and clinical trial referral in the absence of standardized guidelines for managing ctDNA-positive results.